ARS Pharmaceuticals, Inc.

Overview

ARS Pharmaceuticals develops and commercializes neffy, a needle-free intranasal epinephrine product for emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is approved by the U.S. FDA and the European Commission. It is marketed as EURneffy in the EU/UK and 优敏速 in China, with additional regulatory activity underway in other regions.

Product and regulatory status

• Core product: neffy, an intranasal epinephrine delivery system for emergency treatment of anaphylaxis and other Type I allergic reactions.
• U.S.:
  • FDA approval: August 2024.
  • U.S. commercial launch: September 2024.
• Europe:
  • European Commission approval for EURneffy; positive EMA opinion for EURneffy 1 mg (children 15 kg to <30 kg) and market authorization for EURneffy 2 mg.
  • EU/UK launches through collaboration partners.
• Other markets:
  • Approvals in the UK, Japan, Australia, and China as of late 2025.
  • Health Canada regulatory decision expected in 2026.

Commercial strategy

• Multi-channel commercialization including:
  • Direct U.S. sales force.
  • Co-promotion with ALK U.S. (began June 2025).
  • Ongoing programs: neffyexperience, neffyconnect, neffyinSchools, multi-channel advertising, and the Get neffy on Us virtual visits program (launched November 2025).
• Manufacturing: no owned facilities; production and supply secured through third-party manufacturers and suppliers operating under cGMP and related regulations.

Partnerships and geographic footprint

• Key partners and territories:
  • Alfresa (Japan)
  • Seqirus (Australia/New Zealand)
  • Pediatrix (China/Taiwan/Hong Kong/Macau)
  • ALK (Europe/ROW and U.S. co-promotion)
  • Recordati (rights reacquired; previous agreement terminated)
  • Aegis (milestone and royalty arrangements)
• European, Asian, and Australasian launches and regulatory milestones were achieved in 2025 and 2026 under various agreements.

Pipeline and clinical development

• Phase 2b outpatient study in chronic spontaneous urticaria initiated in 2025; interim data expected in H2 2026.
• A single pivotal efficacy study is planned, with potential timing in mid-2027.

Customers and concentration

• As of December 31, 2025:
  • Five customers accounted for 82% of accounts receivable.
  • Five customers accounted for 79% of revenue under collaboration agreements (range 18–43% per customer).
  • Three customers accounted for 94% of revenue under collaboration agreements in 2025.
  • One customer accounted for 86% of revenue under supply agreements.
• As of December 31, 2024:
  • One customer (the Title Agent) accounted for 93% of accounts receivable.
• The company identifies customer concentration risk in product sales and collaboration/supply revenue.

Workforce and sales force

• Internal commercialization employees: ~106 ARS Pharma employees (salesforce, account management, field roles).
• Virtual sales representatives: ~10.
• Co-promotion partner reps (ALK U.S.): ~70 sales reps (began field operations June 2025; targeted coverage up to 9,000 pediatricians and prescribers).
• Planned U.S. sales force expansion: target of ~150 internal sales personnel by Q2 2026.

Corporate headquarters and structure

• Headquarters: San Diego, California; leased office space approximately 9,254 square feet.
• Operating entities: ARS Pharmaceuticals Operations, Inc. and ARS Pharmaceuticals IRL, Limited (Ireland) for regulatory filings and European operations.

Financial snapshot (selected figures)

• Total revenues:
  • 2025: $84.278 million
    • Product revenue, net: $72.192 million
    • Revenue under collaboration agreements: $9.716 million
    • Revenue under supply agreements: $2.370 million
  • 2024: $89.149 million
    • Product revenue, net: $7.255 million
    • Revenue under collaboration agreements: $81.529 million
    • Revenue under supply agreements: $0.365 million
• Net (loss) / income:
  • 2025: Net loss $171.298 million; comprehensive loss $171.393 million
  • 2024: Net income $7.998 million; comprehensive income $8.169 million
• Cost and operating expenses:
  • Cost of goods sold (COGS): 2025 $20.423 million; 2024 $0.977 million
  • R&D: 2025 $13.181 million; 2024 $19.580 million
  • SG&A: 2025 $230.122 million; 2024 $71.675 million
  • Operating loss: 2025 $(179.448) million; 2024 $(3.083) million
• Other items:
  • Other income/(expense), net: 2025 $8.070 million; 2024 $11.369 million
  • Net cash used in operating activities: 2025 $(170.866) million; 2024 $13.548 million
  • Net cash provided by (used in) investing activities: 2025 $56.768 million; 2024 $(106.101) million
  • Net cash provided by financing activities: 2025 $104.598 million; 2024 $72.399 million
  • Cash, cash equivalents, and short-term investments (12/31/2025): $245.0 million
    • Cash and cash equivalents: $41.317 million
    • Short-term investments: $203.669 million

Debt, liquidity, and financing

• Credit facility and term loan:
  • Term loan under Credit Agreement up to $250.0 million.
  • Initial Term A loan funded: $100.0 million (closing Sept 29, 2025).
  • Outstanding balance as of 12/31/2025: $96.374 million (gross proceeds $100.0 million, less debt issuance costs and debt discount).
  • Weighted average interest rate in 2025: 9.49% per annum.
  • Maturity date: Sept 29, 2030.
  • Loan subject to covenants, including limits on additional indebtedness and certain strategic/licensing actions without lender consent.
• Shelf registration: filed in 2025 with Cantor Fitzgerald for potential equity or debt offerings; no securities sold under the shelf as of year-end 2025.

Collaboration, milestone and royalty arrangements

• Alfresa (Japan): upfront $2.0 million; regulatory milestone $5.0 million; aggregate milestone payments recognized by 12/31/2025: $15.0 million; ongoing transfer pricing on future net sales.
• Pediatrix (China/Greater China): upfront $3.0 million; up to $80.0 million in potential sales-based milestones; royalties on future net sales; $4.0 million milestone recognized in 2025.
• Seqirus (Australia/NZ): upfront $0.5 million; up to $2.3 million in remaining milestones; per-unit supply pricing.
• ALK Collaboration: upfront $145.0 million; first commercial sale milestone $5.0 million; potential regulatory/commercial milestones up to $15.0 million; sales-based milestones up to $300.0 million; mid-to-high-teens royalty on net sales.
• ALK Co-Promotion Agreement: base fees plus performance-based bonuses; termination terms; ALK-related SG&A expense recognized in 2025: $6.6 million.
• Recordati: rights reacquired; royalty obligations up to EUR 5.0 million; €5.0 million milestone for first commercial sale recognized in 2025 as intangible assets; amortized through COGS.
• Aegis: milestone payments up to $20.0 million (remaining $9.0 million as of 12/31/2025); mid-single-digit royalty on net product sales.

Inventories and intangible assets

• Inventories (12/31/2025): total $31.422 million (raw materials, work in process, finished goods).
  • Zero-cost inventory on hand: $6.7 million.
• Intangible assets, net (12/31/2025): $14.452 million, including capitalized milestone payments; subject to amortization.

Advertising and promotional spend

• Advertising costs: 2025 $99.8 million (2024 $12.5 million).
• Marketing initiatives and co-promotion activity are material contributors to SG&A growth.

Tax, accounting, and contingencies

• Valuation allowances on deferred tax assets resulted in net deferred tax assets of $0 as of 12/31/2025.
• Unrecognized tax benefits: $7.334 million as of 12/31/2025.
• Net operating losses and credits:
  • Federal NOL carryforward: $150.5 million
  • State NOL carryforward: $16.7 million
  • Federal R&D credits: $4.1 million
  • State credits: $1.0 million
• The impact of OBBBA tax law changes (effective 7/4/2025) is reflected in the financial statements.
• Litigation and contingencies: ongoing patent and other legal proceedings related to neffy (including matters involving Aptar and Lupin). Potential losses are uncertain; no liability was recorded as of 12/31/2025.

Governance and operations

• One operating segment; business managed as a single segment.
• Corporate governance includes a Code of Business Conduct and Ethics and board oversight of management and risks, including cybersecurity.
• The company operates through U.S. and Irish entities to support regulatory filings and international operations.

Summary

• ARS Pharmaceuticals commercializes neffy, the first FDA- and EC-approved needle-free intranasal epinephrine product, and is expanding global distribution through partnerships and direct U.S. commercialization.
• 2025 revenue totaled $84.3 million, primarily from U.S. product sales, with collaboration and supply revenue components. The company reported a net loss of $171.3 million in 2025, driven by higher SG&A and launch-related expenditures.
• Liquidity is supported by cash, short-term investments, and a $100.0 million Term A loan (part of a $250.0 million facility) with a weighted average interest rate of 9.49% in 2025.
• The business includes concentrated customer relationships and multiple milestone- and royalty-based collaboration agreements with meaningful potential future payments.